Home
overview
Every year our pharma events deliver actionable information you need to grow your drug delivery business. This October we have brought together the best drug delivery experts for just two days in London.

This Conference teaches the in's-and-out's of drug delivery technology from top pharmaceutical executives, and drug delivery companies themselves.

The 2004 summit has 18 indepth sessions on oral, inhalation, parenteral and transdermal systems.

The event includes case studies from both large pharma and drug delivery companies. The speakers will evaluate the systems they use and discuss the challenges they overcome.

The meeting provides a unique setting to network with fellow pharma and drug delivery industry professionals and discuss the latest trends.

Indepth sessions covering the following areas:
  • Discover where drug delivery can really add value to your business
  • All the latest news on drug delivery technologies, applications and markets
  • How to 'fast track' the development process for new delivery devices
  • How to apply drug delivery technologies to the development of new and modified products
  • How to develop optimum drug delivery partnerships
  • New innovations in drug delivery for pain management
  • Application of drug delivery for new anti-cancer agents
  • How to improve drug delivery effectiveness
  • How to deliver poorly soluble components
PLUS: The most up-to-date case studies on:
  • Orally Disintegrating Tablets (ODT)
  • Orally Transmucosal (OTM) Technologies
  • Sophisticated oral drug technologies
  • Alternative drug delivery methods
  • Dry Powder Deposition Technologies
  • Nanoparticle Technology
  • Administration of insoluble drugs
  • Protein delivery
  • Novel polymeric systems
  • Controlled release
  • Needle-free strategies
  • Inhalation innovations and technologies
  • High dose pulmonary delivery
  • Oncological drug delivery
  • Pain management systems
  • Vaccine delivery
  • Poorly soluble compounds
  • New transdermal solutions

Previous attendees at our major drug delivery forums include:

Teva, Novartis, Pfizer, Elan, Quintiles, BASF, Cardinal Healthcare, AstraZeneca, SeronoBaxter BioScience, Novo Nordisk, Abbott, Eastman Company, Solvay, Sandoz, SkyePharma, Ipsen Pharma, Genzyme, West Pharmaceutical, Schering, Nektar Therapeutics, Bayer, Alza, Johnson & Johnson, Bristol Myers Squibb, Boehringer Ingelheim, Aventis, Sol-Gel Technologies, Merck Sharp & Dohme, Pliva, CellTech Chiroscience, Unilever, Chugai Pharmaceutical, SkyePharma, Alkermes, The Dow Chemical Company, Biochemie, Guildford Pharmaceuticals, Inhale Therapeutic Systems, Innovative Dermal Applications, Knoll, DanBioSyst, PowderJect, Shire Laboratories, Taisho Pharm, Dura Pharmaceuticals, Chiron, Ratiopharm, Boots Healthcare, Penn Pharmaceuticals, Millennium Pharmaceuticals, and many, many more...

Hear contributions from industry experts including:

Dr Jörg Breitenbach, Director & Head, Soliqs, Abbott Laboratories
Dr Gerrit Hauck, Head, Early Formulation, Aventis
Dr Pramod Gupta, Senior Director, Pharmaceutical Research & Development, Baxter Healthcare
Dr Derek O’Hagan, Senior Director & Head, Vaccine Delivery Research, Chiron Vaccines
Dr David Monteith, Director, Technology & Outside Services, Schering-Plough
Dr Alessandro Martini, Director, Pharmaceutical Research & Development, Nerviano Medical Science
Dr Stephen Farr, Senior Vice President & Chief Scientific Officer, Aradigm
Dr Khurshid Iqbal, Senior Vice President, Global Drug Delivery, West Pharmaceutical Services
Dr Steven Dinh, Vice President, Research & Technology Development, Emisphere Technologies
Dr Raj Khankari, Vice President, Product Development, CIMA Laboratories
Dr Stelios Tzannis, Director, Research & Development, Nektar Therapeutics

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Gerrit Hauck

Dr Gerrit Hauck, Head, Early Formulation, Aventis

9:10 CURRENT TRENDS IN THE DRUG DELIVERY INDUSTRY

Paul Soltys

Paul Soltys, Technology Assesment Manager, Schering Plough Research Institute

  • Drug delivery: moving from part of the pharmaceutical production process to a driving force for innovation and profits
  • Applying drug delivery technologies to the development of new and modified pharmaceutical products
  • Factors affecting drug delivery
  • Developing drug delivery partnerships
  • Regulations governing the use of current and advanced delivery systems
  • Present and future trends in drug delivery technologies
  • 9:50 ADVANCES IN ORALLY DISINTEGRATING TABLETS (ODT) AND ORALLY TRANSMUCOSAL (OTM) TECHNOLOGIES

    Dr Raj Khankari

    Dr Raj Khankari, Vice President, Product Development, CIMA Laboratories

  • Why ODT?
  • ODT market and technologies
  • Critical factors
  • OTM – OraVescent technology
  • Case study
  • 10:30 Morning Coffee

    10:50 GUIDING THE DEVELOPMENT OF SOPHISTICATED ORAL DRUG TECHNOLOGIES IN MAN

    Dr Paul J Clewlow

    Dr Paul J Clewlow, Business Development Director, Pharmaceutical Profiles

  • Review of absorption techniques, such as intubation and engineering-based drug delivery capsules, to ‘map out’ the oral absorption of candidate drugs directly in man
  • How human drug absorption studies early in Phase I ensure that the best compounds are taken forward into ‘full’ clinical development
  • Case histories of absorption studies that have helped guide both clinical and formulation development
  • The use of pharmacoscintigraphy studies (PK evaluation + gamma scintigraphy) to determine whether novel prototype oral delivery technologies are actually delivering the right amount of drug, to the right location in the GI-tract, at the right time
  • Case histories of oral scintigraphy studies that have helped guide new, complex formulation development
  • 11:30 UNIQUE DELIVERY TECHNOLOGY FOR ORAL DRUG DEVELOPMENT

  • Challenges for the oral delivery of macromolecules
  • Overview of Emisphere drug delivery technology
  • Developing non-orally available therapies into safe and effective and commercially viable oral drugs
  • Product pipeline
  • Case studies
  • Dr Steven Dinh

    Dr Steven Dinh, Vice President, Research & Technology, Emisphere Technologies

    Dr Gabriela Mustata

    Dr Gabriela Mustata, Scientist, Computational Chemistry, Emisphere Technologies

    12:10 A NOVEL APPROACH TO ORAL CONTROLLED RELEASE

    Dr Andy Jones

    Dr Andy Jones, Chief Executive Officer, Phoqus Pharmaceuticals

  • Limitations of traditional controlled release systems
  • Drivers of new technology
  • Dry powder deposition: an innovative method for controlled release drug delivery
  • Application
  • Technology in use
  • Therapeutic outcomes
  • 12:50 Networking Lunch

    14:10 APPLICATIONS OF NANOPARTICLE TECHNOLOGY IN ORAL DRUG DELIVERY

    Dr Gerrit Hauck

    Dr Gerrit Hauck, Head, Early Formulation, Aventis

  • How and why nano-particle technology can be used to improve the performance of orally administered drugs
  • Understand the pharmacokinetic benefits that can be gained from using nanoparticle technology
  • Learn which properties of drug compounds determine their suitability for the technology
  • Advantages of this NanoCrystal technology compared to other formulation approaches
  • Applying NanoCrystal technology to a variety of drug candidates
  • Challenges and limitations
  • The future for nanotechnology
  • 14:50 APPLICATION OF NANOPARTICULATE FORMULATIONS FOR ADMINISTRATION OF INSOLUBLE DRUGS

    Dr Pramod Gupta

    Dr Pramod Gupta, Senior Director, Pharmaceutical Research & Development, Baxter Healthcare

  • Rationale for investigating nanoparticle formulations for insoluble drugs
  • Critical success factors in application of nanoparticle formulations
  • Use of computational modeling for predicting probability of success
  • Case study for application in drug discovery and lead molecule selection
  • Case study for injectable formulation development
  • 15:30 Afternoon Tea

    16:00 NOVEL POLYMERIC SYSTEMS FOR CONTROLLED RELEASE PARENTERAL PROTEIN DELIVERY

    Dr Leo deLeede

    Dr Leo deLeede, Managing Director, OctoPlus Technologies

  • Alternative polymers for polylactic-glycolic acid
  • Release without burst effect
  • Release profiles adjusted by compositional parameters
  • Production via solvent evaporation or an all-aqueous process
  • In vitro vs in vivo correlation in animal models
  • In vitro vs in vivo correlation in man
  • 16:40 A NOVEL APPROACH TO TRANSDERMAL DRUG DELIVERY

    Dr Charles Potter

    Dr Charles Potter, Chief Technology Officer, Caretek Medical

  • A needle-free drug delivery technology for the transdermal delivery of therapeutic compounds in a solid or semi-solid dosage form
  • 17:20 NEEDLE-FREE STRATEGIES FOR THE DELIVERY OF BIOTHERAPEUTIC AGENTS

    Dr Stephen Farr

    Dr Stephen Farr, Vice President, Research & Development, Aradigm

  • Towards realisation of non-invasive delivery of systemic peptides and proteins by pulmonary administration
  • Biological barriers for the pulmonary delivery of high molecular weight proteins
  • Alternative strategies, including use of needle-free injectors for subcutaneous administration
  • 18:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Steven Dinh

    Dr Steven Dinh, Vice President, Research & Technology, Emisphere Technologies

    9:10 CAGICLES – A NOVEL PROTEIN AND PEPTIDE DEPOT

    Dr Steffen Panzner

    Dr Steffen Panzner, Chief Executive Officer , Novosom

    9:50 INNOVATIONS IN INHALATION DRUG DELIVERY

    Dr Robert Clayborough

    Dr Robert Clayborough, Group Leader, Drug Delivery Systems, 3M Health Care

  • Developments in inhaled drug delivery over the past decade
  • Major therapeutic applications
  • Case studies
  • Formulations and new technologies required to produce particles of defined characteristics for improved delivery
  • Inventing aerosol delivery devices: propellant-driven metered-dose inhalers, dry powder inhalers and atomisers
  • Reviewing data highlighting innovations and technological advances
  • 10:30 Morning Coffee

    11:00 NASAL DELIVERY OF DRUGS FOR PAIN MANAGEMENT

    Dr Khurshid Iqbal

    Dr Khurshid Iqbal, Senior Vice President, Global Drug Delivery, West Pharmaceutical Services

  • Criteria for drugs that can be used nasally
  • Drug therapy for pain management and the challenge of drug delivery
  • Improving the current effectiveness of nasal delivery
  • Overcoming barriers
  • Patient compliance
  • Perceptions vs facts of potential drug abuse
  • Developing and utilising nasal drug delivery systems comprising Chitosan
  • The latest in clinical trial results for Intranasal Fentanyl
  • 12:10 ANTI-CANCER AGENTS AND DRUG DELIVERY TECHNOLOGIES

    12:50 Networking Lunch

    14:20 DELIVERY OF POORLY SOLUBLE COMPOUNDS

  • Amorphous state
  • Meltrex
  • NanoMorph
  • Xellex
  • Dr Jörg Breitenbach

    Dr Jörg Breitenbach, Director & Head, Soliqs, Abbott Laboratories

    15:00 CHEMICAL ENHANCEMENT OF TRANSDERMAL DRUG DELIVERY

    Dr Thomas Chan

    Dr Thomas Chan, Vice President, Research & Development & Chief Technology Officer, MacroChem

  • Rationale for transdermal delivery of pharmaceuticals
  • Physical enhancement vs chemical enhancement
  • Soft enhancement of percutaneous penetration (SEP®)
  • Product candidates incorporating SEPA
  • Future prospects for transdermal drug delivery
  • 15:40 Afternoon Tea

    16:00 CREATING VALUE USING DRUG DELIVERY

    Dr Stephen Perrett

    Dr Stephen Perrett, Corporate Technology Director, Eurand

  • Valuing technologies
  • Valuing products
  • Valuing companies
  • Investor value
  • Developing the speciality pharma business model
  • 16:40 FAST TRACK DEVELOPMENT OF DRUG DELIVERY DEVICES

    Ian Jobling

    Ian Jobling, Marketing Manager, Perlos

  • The importance of a multi-skilled project management team
  • Attitude to problems and how to overcome them
  • Understanding the ideal product development process from concept to commercialisation
  • Product and mould design
  • Automated assembly
  • Quality and six sigma
  • Production
  • 17:20 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.